Neurocritical Care
Myasthenic Crisis Treatment Selection
Select plasma exchange or IVIG immediately for crisis or imminent respiratory and bulbar failure, while securing the airway, treating precipitants, and sequencing corticosteroids to avoid early worsening. Choice depends on physiologic urgency, access, contraindications, prior response, and complications.
First Decision
Separate impending crisis from manifest crisis before choosing rescue therapy
Treatment selection begins with airway risk and the capacity to rescue deterioration immediately.
Admit a patient with impending crisis to the hospital for close serial assessment of respiratory and bulbar function, with immediate capability to transfer to intensive care if deterioration occurs. Admit manifest crisis to an ICU or step-down unit able to manage respiratory failure and bulbar dysfunction. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis
Define the immediate airway problem clinically: respiratory insufficiency requiring mechanical ventilation or intubation for airway protection constitutes myasthenic crisis. Do not defer intubation in progressive ventilatory failure, ineffective airway protection, or rapidly worsening bulbar weakness while waiting for immunotherapy to work. JAMA+1JAMAPredictors of Extubation Failure in Myasthenic CrisisWileyMyasthenic crisis
At presentation, actively identify and correct reversible precipitants while initiating rescue treatment. Crisis care priorities include airway, respiratory, and circulatory support; confirmation of MG and crisis; evaluation and treatment of acute respiratory failure; elimination of triggers; immunomodulatory treatment; and prevention or treatment of complications. WileyWileyMyasthenic crisis
Obtain serial bedside respiratory and bulbar assessments in impending crisis; worsening function should trigger ICU transfer rather than outpatient or routine-floor observation. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis
Assess for excessive acetylcholinesterase inhibitor effect when clinical worsening is unexplained, because cholinesterase inhibitors increase airway secretions and can aggravate breathing difficulty. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis
Treat PLEX or IVIG as rescue therapy, not as a substitute for airway management; their benefit is rapid relative to chronic immunosuppression but not immediate. Wolters Kluwer+1Wolters KluwerAcute Neuromuscular Respiratory Failure | ContinuumNeurologyClinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection
| Clinical state | Disposition | Immediate treatment selection | Decision trigger |
|---|---|---|---|
| Impending crisis with worsening respiratory or bulbar function | Hospital admission with close observation and capacity for ICU transfer. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis | Initiate PLEX or IVIG when rapid improvement is needed or respiratory/bulbar dysfunction is significant. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis | Progression in respiratory or bulbar impairment warrants ICU-level management. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis |
| Manifest crisis with respiratory failure or airway-protection indication | ICU or capable step-down unit. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis | Provide airway and ventilatory support; initiate PLEX or IVIG as crisis rescue therapy. Neurology+1NeurologyInternational consensus guidance for management of myasthenia gravisNeurologyInternational consensus guidance for management of myasthenia ... | Mechanical ventilation or intubation for airway protection defines the crisis state. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis |
Rescue Immunotherapy
Choose PLEX or IVIG according to urgency, feasibility, and patient-specific risk
Both modalities are accepted short-term therapies; selection should be deliberate rather than protocol automatic.
PLEX and IVIG are both appropriate short-term treatments for life-threatening respiratory insufficiency or dysphagia, significant bulbar dysfunction before surgery, need for rapid response, inadequate response to other treatments, and selected situations before corticosteroid initiation. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis PLEX has strong guideline support and typically reaches maximal efficacy after three to five treatment sessions. BMJBMJEfgartigimod following plasma exchange in the treatment of subjects ...
When physiologic urgency is extreme, PLEX is commonly favored if it can be delivered safely. Comparative literature describes PLEX as producing faster and more noticeable improvement in some studies, and a retrospective crisis cohort found PLEX superior to IVIG for 7-day severity, 2-week ventilation status, and 1-month functional outcome; these data are not definitive enough to establish universal superiority. Wiley+2WileyMyasthenic crisisWolters KluwerMyasthenic crisis : Muscle & Nerve - OvidNeurologyClinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection
Choose IVIG when the logistics, vascular access requirements, or hemodynamic demands of PLEX are unfavorable, or when IVIG is the more deliverable option. Randomized studies in MG exacerbation found IVIG as effective as PLEX at approximately 14 to 15 days, and an earlier trial found no difference in myasthenic muscle score at day 15 among PLEX and IVIG regimens. Nature+1NatureIntravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis | Scientific ReportsWileyMyasthenic crisis In COVID-19-associated crisis, IVIG may be preferable because PLEX removes circulating protective as well as pathogenic antibodies, although the clinical consequence of lowering antiviral antibody titers remains uncertain. NeurologyNeurologyClinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection
Do not interpret failure of one modality as a reason to abandon rescue therapy. If an exacerbation or crisis was not attributable to primary failure of the initial modality, retreatment may be reasonable; after exposure to both therapies, clinicians may retry the modality associated with the better prior response when there is a plausible benefit. nice org uknice org uk3 Committee discussion | Rozanolixizumab for treating antibody-positive generalised myasthenia gravis | Guidance | NICE
Favor PLEX when rapid clinical reversal is the dominant need and the patient can undergo exchange safely. BMJ+2BMJEfgartigimod following plasma exchange in the treatment of subjects ...Wolters KluwerMyasthenic crisis : Muscle & Nerve - OvidNeurologyClinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection
Favor IVIG when PLEX access or tolerance is limiting, or when infection-related concerns make removal of circulating protective antibodies undesirable. NeurologyNeurologyClinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection
For preoperative optimization, three plasmapheresis treatments are recommended in one contemporary review. WileyWileyMyasthenic crisis - Claytor - 2023 - Muscle & Nerve
Do not select efgartigimod, complement inhibition, or other newer targeted agents as routine first-line crisis rescue on the basis of chronic generalized-MG indications; crisis evidence is limited and includes case-based experience for eculizumab after unsuccessful standard rescue treatment. BMJ+1BMJEfgartigimod following plasma exchange in the treatment of subjects ...ScienceDirectEmergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how - ScienceDirect
What the comparative evidence changes
The evidence supports a modality-selection approach rather than a claim that one rescue therapy always dominates. IVIG and PLEX are generally considered equally effective for moderate-to-severe generalized MG exacerbation with a similar duration of benefit, but PLEX may provide a faster or more pronounced response in severe crisis. Nature+2NatureIntravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis | Scientific ReportsWolters KluwerMyasthenic crisis : Muscle & Nerve - OvidNeurologyClinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection Therefore, use urgency, feasibility, prior response, and complication risk to break the tie.
Treatment Sequencing
Sequence corticosteroids after rescue therapy when early worsening could endanger the airway
Rescue immunotherapy provides short-lived benefit; sustained immunosuppression must be timed around its early risks.
Corticosteroids or other immunosuppressive agents are commonly started at the time of PLEX or IVIG to establish a sustained response. Because corticosteroids can transiently worsen myasthenic weakness, it may be safer to wait several days for PLEX or IVIG benefit before initiating corticosteroids when respiratory or bulbar reserve is limited. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis
Corticosteroids remain an important component of crisis treatment in most patients, but they do not replace PLEX or IVIG for acute rescue because clinical response requires weeks and maximal benefit is delayed. Wolters Kluwer+1Wolters KluwerNeuromuscular Disorders in the Intensive Care Unit - ContinuumNeurologyClinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection In a patient who is already unstable, use airway planning and rescue immunotherapy to bridge this delay rather than relying on steroid escalation alone. Neurology+1NeurologyInternational consensus guidance for management of myasthenia gravisNeurologyClinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection
Reassess pyridostigmine and other cholinesterase inhibitors during crisis. Excess cholinesterase inhibition is an uncommon but possible contributor to deterioration, and increased airway secretions can worsen respiratory management. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis In the intubated patient with secretion burden, this tradeoff may favor withholding or reducing the agent until airway control and respiratory mechanics improve.
If starting corticosteroids in a patient with substantial bulbar or respiratory weakness, consider first giving PLEX or IVIG and waiting several days for initial benefit. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis
Use PLEX or IVIG again when clinical deterioration reflects insufficient short-term response; do not expect corticosteroids alone to reverse acute failure. Neurology+1NeurologyInternational consensus guidance for management of myasthenia gravisNeurologyClinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection
Investigate worsening after pyridostigmine for secretion-related respiratory compromise and possible excess cholinesterase effect. NeurologyNeurologyInternational consensus guidance for management of myasthenia gravis
Respiratory Support
Use extubation readiness and pulmonary complications to guide ventilatory strategy
Successful rescue treatment does not eliminate the need for a cautious liberation plan.
Mechanical ventilation is indicated for neuromuscular respiratory failure or when intubation is required for airway protection. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis Continue aggressive respiratory support while PLEX or IVIG takes effect; intubation itself should not be viewed as rescue-treatment failure because crisis is defined by the need for ventilatory support or airway protection. JAMA+1JAMAPredictors of Extubation Failure in Myasthenic CrisisNeurologyInternational consensus guidance for management of myasthenia gravis
Before extubation, integrate bedside respiratory performance with pulmonary complication status. In a study of myasthenic crisis, male sex, prior crisis, atelectasis, and intubation longer than 10 days were associated with extubation failure. Among patients evaluated for reintubation, lower pH, lower forced vital capacity at extubation, atelectasis, and post-extubation BiPAP use predicted reintubation. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis
Treat atelectasis and other pulmonary complications before a marginal extubation attempt whenever possible. Noninvasive ventilation may help avoid reintubation in selected patients, but the association between post-extubation BiPAP use and reintubation identifies a high-risk group rather than proof that BiPAP causes failure. JAMA+1JAMAPredictors of Extubation Failure in Myasthenic CrisisWileyMyasthenic crisis - Claytor - 2023 - Muscle & Nerve
Delay extubation when forced vital capacity is declining, acidemia persists, or atelectasis has not been addressed; each was associated with a higher reintubation risk in crisis cohorts. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis
Anticipate prolonged ventilatory support in patients with prior crisis or intubation exceeding 10 days. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis
Use noninvasive ventilation selectively after extubation, with close monitoring for fatigue, secretion retention, or recurrent airway-protection failure. JAMA+1JAMAPredictors of Extubation Failure in Myasthenic CrisisWileyMyasthenic crisis - Claytor - 2023 - Muscle & Nerve
| Finding | Association | Bedside implication |
|---|---|---|
| Atelectasis | Associated with extubation failure and reintubation. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis | Address pulmonary collapse before extubation and monitor closely afterward. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis |
| Intubation longer than 10 days | Associated with extubation failure. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis | Plan a higher-risk liberation strategy rather than a routine extubation trial. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis |
| Lower pH at extubation | Predicted reintubation in analyzed patients. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis | Correct or explain acidemia before proceeding with extubation. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis |
| Lower forced vital capacity at extubation | Predicted reintubation. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis | Use low FVC as a warning against extubating on apparent limb-strength improvement alone. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis |
| BiPAP after extubation | Associated with reintubation. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis | Treat post-extubation NIV requirement as a marker for intensified surveillance. JAMAJAMAPredictors of Extubation Failure in Myasthenic Crisis |
Exceptions
Escalate early in immune checkpoint inhibitor-associated and refractory crisis
Etiology and prior rescue response can change the urgency and acceptable treatment sequence.
Immune checkpoint inhibitor-associated MG can progress rapidly irrespective of initial apparent severity. In a systematic review and single-center series, 14 of 38 patients initially treated with corticosteroids alone progressed to respiratory failure, including four initially presenting with ocular symptoms; 18 of 19 patients receiving IVIG or PLEX first line improved. BMJBMJImmune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature | Journal for ImmunoTherapy of Cancer Hospitalize these patients and use early IVIG or PLEX rather than waiting for steroid response when MG is suspected clinically. BMJBMJImmune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature | Journal for ImmunoTherapy of Cancer
For refractory crisis after standard PLEX or IVIG, do not substitute case-report evidence for established rescue pathways. Eculizumab has been reported in refractory crisis, including successful extubation after failed PLEX and high-dose prednisone, but the evidence base consists of a case report and 19 additional reported cases. ScienceDirectScienceDirectEmergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how - ScienceDirect If considered, recognize the need for prompt meningococcal vaccination and antibiotic prophylaxis described in that report; this is an exceptional rescue decision rather than routine first-line care. ScienceDirectScienceDirectEmergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how - ScienceDirect
After acute stabilization, transition to long-term MG management rather than repeating rescue therapy indefinitely. The broader treatment armamentarium includes corticosteroids, nonsteroidal immunosuppressive therapy, FcRn inhibitors, complement inhibitors, B-cell-directed therapy, and thymectomy; thymectomy is required for thymoma and can benefit AChR-antibody-positive generalized nonthymomatous MG. BMJ+1BMJEfgartigimod following plasma exchange in the treatment of subjects ...BMJMyasthenia gravis - Symptoms, diagnosis and treatment | BMJ Best Practice US
In immune checkpoint inhibitor-associated MG, do not use isolated ocular symptoms to justify outpatient observation or corticosteroids alone. BMJBMJImmune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature | Journal for ImmunoTherapy of Cancer
Consider refractory targeted therapy only after standard rescue approaches have failed or are contraindicated, with infection-prevention requirements explicitly addressed for complement inhibition. ScienceDirectScienceDirectEmergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how - ScienceDirect
Assess for thymoma as part of definitive MG management; thymoma requires thymectomy. BMJBMJMyasthenia gravis - Symptoms, diagnosis and treatment | BMJ Best Practice US
References
- Efgartigimod following plasma exchange in the treatment of subjects ... — neurologyopen.bmj.com · neurologyopen.bmj.com
- Myasthenia gravis - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com · bestpractice.bmj.com
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature | Journal for ImmunoTherapy of Cancer — jitc.bmj.com · jitc.bmj.com
- Predictors of Extubation Failure in Myasthenic Crisis — jamanetwork.com · jamanetwork.com
- Noninvasive Ventilation in Myasthenic Crisis - JAMA Network — jamanetwork.com · jamanetwork.com
- Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis | Scientific Reports — www.nature.com · www.nature.com
- Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis | Scientific Reports — www.nature.com · www.nature.com
- Neuromuscular Disorders in the Intensive Care Unit - Continuum — journals.lww.com · journals.lww.com
- Acute Neuromuscular Respiratory Failure | Continuum — journals.lww.com · journals.lww.com
- Risk factors of myasthenic crisis after thymectomy for thymoma ... — academic.oup.com · academic.oup.com
- Myasthenic crisis — onlinelibrary.wiley.com · onlinelibrary.wiley.com
- Thymectomy for non-thymomatous myasthenia gravis — academic.oup.com · academic.oup.com
- Myasthenic crisis: Guidelines for prevention and treatment — www.sciencedirect.com · www.sciencedirect.com
- Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how - ScienceDirect — www.sciencedirect.com · www.sciencedirect.com
- Myasthenic crisis: Guidelines for prevention and treatment - ScienceDirect — www.sciencedirect.com · www.sciencedirect.com
- Effect of Intravenous Immunoglobulin or Plasmapheresis in Myasthenic Crisis and Worsening Myasthenia Gravis Compared to Without Rescue Treatment - ScienceDirect — www.sciencedirect.com · www.sciencedirect.com
- Myasthenic crisis - Claytor - 2023 - Muscle & Nerve — onlinelibrary.wiley.com · onlinelibrary.wiley.com
- 1670: COMPARATIVE EFFICACY OF IVIG AND PLASMA... - Lippincott — journals.lww.com · journals.lww.com
- Myasthenic crisis : Muscle & Nerve - Ovid — journals.lww.com · journals.lww.com
- International consensus guidance for management of myasthenia gravis — www.neurology.org · www.neurology.org
- 3 Committee discussion | Rozanolixizumab for treating antibody-positive generalised myasthenia gravis | Guidance | NICE — www.nice.org.uk · www.nice.org.uk
- International consensus guidance for management of myasthenia ... — www.neurology.org · www.neurology.org
- Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection — www.neurology.org · www.neurology.org
- Myasthenia gravis — www.neurology.org · www.neurology.org